Lab Automation in Drug Discovery Global Market Report 2024

The lab automation in drug discovery market size has grown strongly in recent years. It will grow from $6.13 billion in 2023 to $6.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The expansion observed in the historical period can be attributed to several factors, including the increasing complexity of drug discovery processes, a demand for improved efficiency and cost reduction, a growing need for high-throughput screening capabilities, rising labor costs, and the pressure to accelerate drug development timelines. These factors collectively contributed to the growth of lab automation in drug discovery during that timeframe.

The lab automation in drug discovery market size is expected to see strong growth in the next few years. It will grow to $7.96 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of drug pipelines among pharmaceutical companies, the rise in personalized medicine and precision therapeutics, an increasing focus on rare diseases and orphan drugs, a growing demand for remote and decentralized clinical trials, and the emergence of microfluidics and lab-on-a-chip technologies. Key trends expected in the forecast period include the proliferation of modular and customizable automation solutions, the adoption of cloud-based platforms for data management and collaboration, the growth of automation in emerging markets, the rise of virtual drug discovery companies leveraging automation and digital technologies, and the development of standardized protocols and interoperable systems. These factors collectively contribute to the projected growth in lab automation in drug discovery.

The growing demand for precision medicine is anticipated to drive the growth of lab automation in the drug discovery market. Precision medicine, also known as personalized medicine, tailors medical treatment and prevention strategies based on individual variability in genes, environment, and lifestyle. Lab automation plays a pivotal role in accelerating research, enhancing experimental repeatability, and improving the efficiency of precision medicine and drug discovery procedures. This, in turn, leads to the development of more effective medicines and diagnostics tailored to individual patients. According to the Personalized Medicine Coalition (PMC) in October 2022, over 75,000 genetic testing products and 300 personalized medicines are expected to be available in the market, catering to individuals with various types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. The rising demand for precision medicine is a key driver propelling the growth of lab automation in the drug discovery market.

Prominent companies operating in the lab automation in the drug discovery market are strategically focusing on developing advanced solutions, particularly rapid idea-to-data solutions, to gain a competitive edge. A rapid idea-to-data solution refers to a streamlined process or platform enabling individuals or organizations to quickly transform ideas or concepts into actionable insights or data-driven results. In April 2022, Strateos Inc., a US-based biotechnology company, introduced a rapid idea-to-data solution for small molecule discovery on its cloud lab automation-as-a-service platform. Specifically designed for small-molecule discovery in drug development, this lab automation tool operates on the on-demand and scalable Strateos Cloud Lab Automation-as-a-Service Platform. The platform includes linked robotic automation with 23 workcells and hundreds of instruments, facilitating early lead generation through lead optimization. Users can design compounds in the cloud and have them automatically assembled and tested using various methods such as cell-based, biochemical, and structured-activity relationship (SAR) assessments.

In March 2023, Brooks Automation, a US-based automation solution company, successfully acquired Aim Lab Automation Technologies Pty Ltd. for an undisclosed amount. This strategic acquisition aims to expand Brooks' presence in clinical diagnostics and drive technological advancements, significantly impacting lab automation in the drug discovery market. Aim Lab Automation Technologies Pty Ltd., based in Australia, provides robotic automation instrumentation and modules, along with automation solutions designed to enhance processes in drug discovery labs.

Major companies operating in the lab automation in drug discovery market are Thermo Fisher Scientific Inc., Abbott Diagnostics, Roche Holdings Inc., Beckman Coulter, Siemens Healthineers, Becton Dickinson and Company, Agilent Technologies Inc., PerkinElmer Inc., Endress+Hauser, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN, Beckhoff Automation GmbH & Co. KG, Eppendorf AG, Tecan Group Ltd., Brooks Automation Inc., Hamilton Company, AbCellera Biologics Inc., Hudson Robotics Inc., OpenTrons Labworks Inc., Quanterix Corporation, The Technology Partnership, HighRes Biosolutions Inc., Biosero Inc., Peak Analysis and Automation Ltd., Aurora Biomed Inc., Arctoris, Inveox GmbH, Synthace, Synchron Lab Automation.

North America was the largest region in the lab automation in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lab automation in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lab automation in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lab automation in drug discovery refers to the utilization of advanced technologies and robotics to streamline and optimize laboratory processes associated with new drug development and research. This approach aims to significantly improve the efficiency and success rate of drug discovery efforts by automating repetitive tasks and integrating sophisticated instruments and software. Automation in drug discovery laboratories can cover a wide range of activities, from high-throughput screening of compounds to data analysis and interpretation, allowing researchers to focus on more complex and creative aspects of their work.

The primary types of lab automation in drug discovery include automated liquid handlers, automated plate handlers, robotic arms, automated storage and retrieval systems, among others. Automated liquid handlers are machines specifically designed to dispense and handle liquids automatically. They are frequently employed in laboratories for precise and efficient liquid handling tasks such as pipetting and dilution. These automation solutions comprise various components, including instruments, software, and services, and find applications in high-throughput screening, compound management, sample preparation, and other processes. These technologies are utilized by various end-users, including biotechnology and pharmaceutical industries, research institutes, and others.

The lab automation in drug discovery research report is one of a series of new reports that provides lab automation in drug discovery market statistics, including the lab automation in drug discovery industry's global market size, regional shares, competitors with lab automation in drug discovery market share, detailed lab automation in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the lab automation in drug discovery industry. This lab automation in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lab automation in drug discovery market consists of revenues earned by entities by providing services such as compound screening, assay development, high-throughput screening, data analysis, and optimization of drug candidates. The market value includes the value of related goods sold by the service provider or included within the service offering. The lab automation in drug discovery market also includes sales of robotics and automated workstations, screening systems, plate readers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.